Table 5.
AFRO | AMRO | EMRO | SEARO | WPRO** | GAVI-eligible | Global | |
---|---|---|---|---|---|---|---|
ETEC vaccination | |||||||
Number of countries ICER < 3 X GDP | 17 | 3 | 4 | – | 3 | 19 | 27 |
[7; 21] | [1; 4] | [2; 5] | – | [ND; 3] | [6; 24] | [10; 34] | |
Total deaths* averted (1000 s) | 45.6 | 1.0 | 13.6 | – | 0.4 | 35.0 | 60.7 |
[23.6; 71.3] | [0.2; 1.5] | [2.7; 19.4] | – | [ND; 0.6] | [10.0; 59.3] | [26.8; 116.1] | |
Total deaths* averted/100,000 FVC*** | 7.2 | 2.5 | 4.6 | – | 2.2 | 5.4 | 6.1 |
[5.5; 9.9] | [1.2; 3.7] | [2.8; 6.2] | – | [ND; 3.0] | [4.1; 7.6] | [3.9; 8.0] | |
Total DALYs* averted (1000 s) | 1,561 | 35 | 464 | – | 13 | 1,194 | 2,073 |
[807; 2,440] | [8; 51] | [93; 659] | – | [ND; 19] | [341; 2,026] | [915; 3,970] | |
Total DALYs* averted/100,000 FVC*** | 246 | 86 | 155 | – | 76 | 185 | 209 |
[190; 340] | [40; 128] | [94; 211] | – | [ND; 100] | [140; 260] | [133; 273] | |
Vaccination costs (millions US$) | 2,259 | 146 | 1,055 | – | 60 | 2,295 | 3,520 |
[1,550; 2,944] | [69; 183] | [332; 1,631] | – | [ND; 95] | [821; 3,026] | [2,333; 7,928] | |
Vaccination costs/100,000 FVC*** | 355,702 | 356,373 | 353,238 | – | 352,397 | 356,570 | 354,931 |
[274,110; 561,392] | [265,267; 557,867] | [253,764; 557,408] | – | [ND; 546,333] | [274,842; 563,324] | [272,039; 561,229] | |
Administration costs/100,000 FVC*** | 98,453 | 99,057 | 96,233 | – | 95,475 | 99,234 | 97,757 |
[65,886; 125,759] | [63,968; 126,238] | [60,760; 123,783] | – | [ND; 122,304] | [66,462; 127,364] | [65,076; 124,893] | |
Medical costs averted (millions US$) | 82 | 10 | 43 | – | 2 | 80 | 137 |
[34; 127] | [3; 17] | [7; 62] | – | [ND; 4] | [13; 125] | [49; 374] | |
ICER (2016 US$/DALY) | 1,395 | 3,871 | 2,181 | – | 4,474 | 1,856 | 1,632 |
[982; 2,154] | [2,479; 9,664] | [1,203; 3,681] | – | [ND; 6,655] | [1,206; 2,762] | [1,449; 2,530] | |
Shigella vaccination | |||||||
Number of countries ICER < 3 X GDP | 18 | 3 | 8 | – | – | 22 | 29 |
[8; 23] | [1; 4] | [5; 8] | – | – | [10; 27] | [14; 37] | |
Total deaths* averted (1000 s) | 52.7 | 1.1 | 53.0 | – | – | 76.5 | 106.8 |
[27.1; 91.0] | [0.2; 1.6] | [31.9; 71.9] | – | – | [41.1; 121.4] | [59.4; 188.3] | |
Total deaths* averted/100,000 FVC*** | 7.9 | 2.6 | 10.7 | – | – | 10.1 | 8.8 |
[6.1; 10.9] | [1.2; 3.9] | [8.1; 15.2] | – | – | [8.2; 14.2] | [5.3; 11.9] | |
Total DALYs* averted (1000 s) | 1,746 | 36 | 1,777 | – | – | 2,556 | 3,559 |
[901; 3,010] | [8; 53] | [1,070; 2,412] | – | – | [1,377; 4,041] | [1,983; 6,255] | |
Total DALYs* averted/100,000 FVC*** | 260 | 89 | 357 | – | – | 339 | 294 |
[202; 361] | [41; 130] | [270; 508] | – | – | [273; 476] | [176; 395] | |
Vaccination costs (millions US$) | 2,386 | 146 | 1,763 | – | – | 2,693 | 4,296 |
[1,650; 3,237] | [71; 187] | [1,250; 2,426] | – | – | [1,811; 3,597] | [3,030; 9,202] | |
Vaccination costs/100,000 FVC*** | 355,503 | 356,373 | 354,360 | – | – | 356,897 | 355,062 |
[275,835; 560,639] | [268,790; 558,302] | [272,641; 560,870] | – | – | [276,720; 562,627] | [273,263; 560,780] | |
Administration costs/100,000 FVC*** | 98,273 | 99,057 | 97,243 | – | – | 99,529 | 97,876 |
[66,166; 125,794] | [64,733; 125,497] | [65,110; 124,785] | – | – | [67,012; 127,662] | [65,318; 124,896] | |
Medical costs averted (millions US$) | 98 | 10 | 213 | – | – | 184 | 321 |
[38; 151] | [3; 17] | [74; 302] | – | – | [81; 269] | [116; 652] | |
ICER (2016 US$/DALY) | 1,311 | 3,750 | 872 | – | – | 981 | 1,117 |
[899; 1,960] | [2,465; 9,416] | [539; 1,260] | – | – | [713; 1,366] | [1,045; 1,687] |
Total deaths and DALYS are the sum of burden attributed to diarrhea from ETEC or Shigella infection and ETEC- or Shigella-induced deaths from other infectious diseases.
“ND” indicates ‘not defined’ as there were no WPRO countries that met the threshold under the predicted lower bounds (2.5%) of the 95% uncertainty intervals.
Fully vaccinated children (FVC): Number of eligible children who received all three doses of the vaccine.